Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Hisamitsu Pharmaceutical Co., Inc.
- 6,810.00 JPY
- -70.00
- -1.02%
Japan
Oct 19, 2018Ticker
TKS(4530)Prev. close
6,880Market cap (JPY)
654,734MMarket cap (USD)
5,820.12MShares
95.16M
In the news
- Hisamitsu's 9-month operating profit likely down 11% Dec 26, 2017
- Hisamitsu's interim operating profit seen down 3% Sep 23, 2017
- Tourists to Japan now spending more on the cheap Aug 29, 2017
- Hisamitsu's quarterly profit seen hurting on competition from generics Jun 23, 2017
- Hisamitsu Pharma profit seen 13% slimmer Jun 28, 2016 See more articles on Hisamitsu Pharmaceutical Co., Inc.
Business Summary
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, Lifecella, and Keplat brands. It also provides ethical pharmaceuticals, over the counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
Financial Highlights
| Feb 2018 | JPY | USD |
| Revenue | 147,870M | 1,327.30M |
| Gross Profit | 92,182M | 827.44M |
| Operating income | 26,346M | 236.48M |
| Income before tax | 27,694M | 248.58M |
| Net income | 19,120M | 171.62M |
| EBITDA | 32,351M | 290.38M |
| Diluted EPS | 228.34 | 2.04 |
| Dividends Per Share | 82 | 0.73 |
| Total Assets | 299,913M | 2,810.67M |
| Total liabilities | 54,681M | 512.45M |
| Total equity | 244,000M | 2,286.67M |
| Operating cash flow | 30,453M | 273.35M |
| Currency in JPY | Currency in USD |
Historical Data
| Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Feb 2018 | |
| Revenue | 150,635M | 156,743M | 161,852M | 145,925M | 147,870M |
| Gross Profit | 94,291M | 98,734M | 102,465M | 91,840M | 92,182M |
| Operating income | 19,123M | 20,527M | 27,730M | 26,306M | 26,346M |
| Income before tax | 33,727M | 29,416M | 27,922M | 29,984M | 27,694M |
| Net income | 21,357M | 18,784M | 17,784M | 20,395M | 19,120M |
| EBITDA | 26,615M | 28,140M | 36,275M | 33,674M | 32,351M |
| Diluted EPS | 249.30 | 219.27 | 208.76 | 241.14 | 228.34 |
| Dividends Per Share | 70 | 80 | 81 | 81.50 | 82 |
| Total Assets | 251,852M | 285,440M | 284,954M | 278,820M | 299,913M |
| Total liabilities | 55,544M | 63,386M | 58,859M | 49,611M | 54,681M |
| Total equity | 195,443M | 221,023M | 225,095M | 228,108M | 244,000M |
| Operating cash flow | 35,845M | 23,232M | 30,923M | 19,910M | 30,453M |
| Feb 2014 | Feb 2015 | Feb 2016 | Feb 2017 | Feb 2018 | |
| Revenue | 1,512.76M | 1,446.77M | 1,340.64M | 1,347.79M | 1,327.30M |
| Gross Profit | 946.92M | 911.33M | 848.73M | 848.25M | 827.44M |
| Operating income | 192.04M | 189.46M | 229.69M | 242.96M | 236.48M |
| Income before tax | 338.70M | 271.51M | 231.28M | 276.93M | 248.58M |
| Net income | 214.47M | 173.38M | 147.30M | 188.37M | 171.62M |
| EBITDA | 267.28M | 259.73M | 300.47M | 311.02M | 290.38M |
| Diluted EPS | 2.50 | 2.02 | 1.72 | 2.22 | 2.04 |
| Dividends Per Share | 0.70 | 0.73 | 0.67 | 0.75 | 0.73 |
| Total Assets | 2,467.56M | 2,387.72M | 2,524.50M | 2,492.02M | 2,810.67M |
| Total liabilities | 544.20M | 530.22M | 521.45M | 443.41M | 512.45M |
| Total equity | 1,914.88M | 1,848.86M | 1,994.19M | 2,038.77M | 2,286.67M |
| Operating cash flow | 359.97M | 214.43M | 256.14M | 183.89M | 273.35M |
Valuation Measures
| Feb 2018 | |
| PER | 33.87 |
| ROA | 6.60% |
| ROE | 8.09% |
| Operating margin | 17.81% |
| Profit margin | 12.93% |
Key executives
- Chairman & Chief Executive Officer: Hirotaka Nakatomi
- President, COO & Representative Director: Kazuhide Nakatomi
- Director, Manager-Finance & Investor Relations: Shinichiro Takao
- Executive Officer, GM-Research & Development: Takaaki Terahara
- Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi
Shareholders
- Hisamitsu Pharmaceutical Co., Inc. (12.0%)
- Government of Japan (5.3%)
- Bank of Tokyo Mitsubishi UFJ Pension Fund (4.6%)
- Nishi Nippon City Bank Pension Fund (4.5%)
- Nippon Life Insurance Co. (4.1%)
- Fukuoka Financial Group, Inc. (3.8%)
- The Bank of Saga Ltd. (2.4%)
- Hisamitsu Pharmaceutical Business Association (2.3%)
- Sumitomo Mitsui Banking Pension Fund (2.1%)
- Mitsubishi UFJ Financial Group, Inc. (1.9%)
Contact Details
- Website:http://www.hisamitsu.co.jp
- Phone: +81.942.83.2101
Related Companies
- Nakatomi Memorial Foundation
- Hisamitsu Pharmaceutcal Co. Ltd.
- Hisamitsu Farmaceutica do Brasil Ltda.
- Hisamitsu Vietnam Pharmaceutical Co. Ltd.
- PT Hisamitsu Pharma Indonesia
- Hisamitsu UK Ltd.
- Hisamitsu Pharmaceutical Business Association
- Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co. Ltd.
- CRCC Media Co., Ltd.
- Hisamitsu America, Inc.
- Saga City Vision KK
- Hisamitsu US, Inc.
- SSP Co. Ltd. /Ethical Medicine Division/
- Noven Pharmaceuticals, Inc.
Competitors
- KemPharm, Inc.
- DURECT Corporation
- TherapeuticsMD, Inc.
- Corium International, Inc.
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 19 Oct, 2018You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
Your full access to the Nikkei Asian Review has expired
